In order to preserve muscle mass during catabolic states, investigators are actively searching for a specific inhibitor of MuRF1, the only known E3 ligase able to target muscle contractile proteins for their degradation. However, it is unknown what would be the consequences of such inhibitors on other organs, both in the short and long term. Indeed, skeletal muscles can provide amino acids for liver gluconeogenesis, which is a crucial adaptation for maintaining glucose homeostasis upon elevated energy demands (e.g. during prolonged starvation). Comparing 3-month-old wild-type and MuRF1-KO mice, we measured tissue weights, liver glycogen, lipid and protein content, and liver biochemical composition using Fourier Transform Infrared (FTIR) spectrometry in control animals and in dexamethasone (Dex) treated animals. Dex induces a catabolic situation with muscle atrophy and lipid deposits in the liver. In response to Dex treatment, liver glycogen, lipid and protein content increased in wild type (WT) and MuRF1-KO mice. We found that MuRF1 deletion differentially affected organs weights, the liver of KO mice being hypertrophied upon Dex treatment when compared to WT mice. Upon Dex treatment, muscle mass was preserved in MuRF1-KO mice and, by contrast, liver lipid content increased more in these animals than in WT mice. PLS-DA analysis of FTIR showed that the levels of 13 markers were significantly altered in KO vs. WT mice, witnessing profound alterations of lipid, protein and glycogen content in the liver due to the absence of MuRF1. Using Nile red and oil red O lipid staining, we also found that both membrane-linked lipids and intracellular lipid droplets were altered due to the absence of MuRF1. Altogether, it seems that when the liver is deprived of the possibility to obtain amino acids from muscle upon Dex treatment, there is a concomitant increase in tissue weight and anabolic activity.